Depression is a serious mental health condition that can have a significant impact on a person’s quality of life. As a result, it is important to ensure that those suffering from depression receive the best possible care and treatment. One of the most common treatments for depression is the use of Selective Serotonin Reuptake Inhibitors (SSRIs), such as Lexapro. It is not uncommon for doctors to increase the dosage of Lexapro from 10mg to 20mg in order to maximize its benefits. In this article, we will explore the potential benefits of doubling down on Lexapro dosage and examine the potential risks associated with increasing the dosage.
Lexapro is a brand name for the generic drug escitalopram. It is an SSRI, which stands for selective serotonin reuptake inhibitor. SSRIs work by increasing the amount of serotonin, a neurotransmitter, in the brain. This helps to improve mood and reduce symptoms of depression. Lexapro is used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
The standard dosage of Lexapro is 10mg once a day. This is the recommended starting dose for adults and adolescents aged 12 and over. It is important to note that the dosage may be adjusted depending on the individual’s response to the medication.
Increasing the dosage of Lexapro from 10mg to 20mg can have a number of potential benefits. These include:
One of the primary benefits of increasing the dosage of Lexapro is that it can lead to an improved response to treatment. Studies have shown that increasing the dosage of Lexapro can lead to a greater reduction in symptoms of depression and anxiety. In one study, patients who increased their dosage from 10mg to 20mg experienced a greater reduction in symptoms of depression after 8 weeks of treatment compared to those who remained on the 10mg dosage.
Increasing the dosage of Lexapro can also reduce the risk of relapse. Studies have shown that patients who increased their dosage from 10mg to 20mg had a lower risk of relapse compared to those who remained on the 10mg dosage. This suggests that increasing the dosage of Lexapro can help to maintain remission and reduce the risk of relapse.
Increasing the dosage of Lexapro can also reduce the risk of side effects. Studies have shown that increasing the dosage of Lexapro can lead to a reduction in the incidence of side effects, such as nausea, headache, and sexual dysfunction. This suggests that increasing the dosage of Lexapro can help to reduce the risk of side effects.
Although there are potential benefits to increasing the dosage of Lexapro, there are also potential risks associated with this decision. These include:
Increasing the dosage of Lexapro can lead to an increased risk of side effects. This is because higher doses of the medication can lead to an increased risk of certain side effects, such as nausea, headache, and sexual dysfunction. It is important to discuss the potential risks and benefits of increasing the dosage of Lexapro with your doctor before making any changes.
Increasing the dosage of Lexapro can also lead to interactions with other medications. This is because higher doses of the medication can lead to an increased risk of interactions with other medications, such as pain medications and blood thinners. It is important to discuss the potential risks and benefits of increasing the dosage of Lexapro with your doctor before making any changes.
Finally, increasing the dosage of Lexapro can lead to an increased risk of overdose. This is because higher doses of the medication can lead to an increased risk of overdose if the medication is not taken as prescribed. It is important to discuss the potential risks and benefits of increasing the dosage of Lexapro with your doctor before making any changes.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation